艾美捷科技代理InSCREENeX品牌全系列产品

InSCREENeX GmbH成立于2009年，位于德国布伦瑞克亥姆霍兹感染研究中心内，是一家专注于开发细胞筛选技术的德国生物技术公司，InSCREENeX生产用于药物开发的细胞系统。InSCREENeX在该领域拥有超过15年的哺乳动物细胞基因修饰专业知识，在此期间成功开发了SCREENflex和CI-SCREEN这两项高度创新的技术。

利用SCREENflex技术，可以根据客户需求创建稳定的重组哺乳动物细胞。这种方法具有以下优势：快速建立所需的测试系统、目标基因的稳定表达，以及能够以不同水平调控该基因的表达。SCREENflex 技术具有普适性，已成功应用于建立多种蛋白质类别，例如 GPCRs（G蛋白偶联受体）、离子通道、抗体和细胞因子。InSCREENeX公司的产品包括稳定表达细胞系、永生化细胞系以及细胞培养试剂。

▍InSCREENeX产品线

● 稳定表达细胞系：包括离子通道、GPCRs、整合素及其他受体的稳定过表达细胞系

● 永生化细胞系：来自不同物种的功能性永生化细胞系。

● Reagents and Consumables产品

▍InSCREENeX提供的服务

● Landing Pad Cells：将目标单拷贝整合到CHO、HEK293 和 Llama主细胞系中，快速生成细胞系并进行变体库整合。

● Random Integration：通过病毒或非病毒方法将目标基因随机整合到任何细胞系中。

● Cell culture services：高度定制化的细胞系服务，包括细胞库构建、细胞存储、制备：细胞沉淀(Pellets)、细胞裂解液(Lysates)、DNA、RNA、培养基优化，原代细胞分离与分选等。

● Assay services：建立并运行检测方法，包含检测方法建立与优化，代运行检测服务等。

● Molecular biology services：包含克隆构建，质粒制备，DNA/RNA分离提取与制备，慢病毒生产等服务。

Innovative Research of America(IRA) 是一家致力研发于药物定量定时缓释系统的专业化公司，又称Matrix-Driven Delivery (MDD) 给药系统。该给药系统由一个可生物吸收的基质组成，含有定量可控的活性给药成分，可以以设定的剂量在一定时间范围内进行给药。

Since it is not easy to administer drugs and hormones orally to research animals, several delivery methods have been devised as alternatives.  However, most scientists continue to labor with unreliable injectables to conduct their research.

Matrix-Driven Delivery (MDD) Pellet（MDD片剂）的优势

Saves time

Ready-to-implant

Insures controlled product release over time

Avoids "peak and valley" effects

Guarantees consistent product preparation

Extends product life against spontaneous breakdown

Extends product life against host-related breakdown

Minimizes experimental variables

Insures safety of the experimenter

Reduces neurophysiological trauma to animal/no excessive handling

Generates more meaningful and reproducible results

Superior to conventional delivery methods

Enhances experimental efficiency

Frees valuable time for creative research

Saves money

Innovative Research of America的主要产品包括：

ANTIBIOTICS

ANTI-INFLAMMATORY AGENTS

ANTI-NEOPLASTICS

CATECHOLAMINES & RELATED PRODUCTS

CORTICOIDS & DIURETICS

ESTROGENS & ANTI-ESTROGENS

FATTY ACIDS

MISCELLANEOUS PRODUCTS

NUCLEOTIDE RELATED PRODUCTS

PLACEBO

PROGESTINS

PROSTAGLANDINS

THYROIDS

VITAMINS

更多详情请联系 

艾美捷科技有限公司

全国服务热线：400-6800-868

邮箱：sales@amyjet.com

网站：www.amyjet.com

艾美捷科技特约代理Avidity Biosciences公司产品。

Avidity Biosciences公司位于美国加州La Jolla，是一家专门从事抗体寡核苷酸结合物（AOC™）技术开发的生物技术公司，此项技术结合了单抗组织选择性和寡核苷酸疗法的精确性，克服了寡核苷酸给药屏障。

Avidity Biosciences is a privately-held biotech company pioneering Antibody Oligonucleotide Conjugates (AOC™). AOCs combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapeutics to overcome barriers to the delivery of oligonucleotides and target genetic drivers of disease.

Antibody oligonucleotide conjugate (AOC™) technology

Avidity’s antibody oligonucleotide conjugate (AOC™) technology utilizes antibodies to target cells and tissues of interest and facilitate the uptake and internalization of oligonucleotide payloads. By combining the cellular and tissue selectivity of antibodies with the selectivity and efficiency of oligo-based approaches, Avidity has demonstrated modulation of disease-related RNAs in diverse cell types and tissues including muscle, heart, liver, tumors and immune cells.